2
|
Daudén E, Puig L, Ferrándiz C, Sánchez-Carazo JL, Hernanz-Hermosa JM. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol 2016; 30 Suppl 2:1-18. [PMID: 26812550 DOI: 10.1111/jdv.13542] [Citation(s) in RCA: 90] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Accepted: 11/09/2015] [Indexed: 12/28/2022]
Abstract
Psoriasis is a highly prevalent disease with a major impact on quality of life; therefore, appropriate patient management is mandatory. Given that many issues in psoriasis are controversial and not clearly defined by evidence-based medicine, management of psoriasis is very variable. Expert consensus can generate practical guidelines for optimization of patient care. Much has changed since 2009, when the Consensus Document on the Evaluation and Treatment of Moderate to Severe Psoriasis was published by the Spanish Psoriasis Group (GEP) of the Spanish Academy of Dermatology and Venereology (AEDV). The objective of the present consensus document is to provide the dermatologist with updated recommendations for the evaluation and treatment of patients with moderate-to-severe plaque psoriasis. All active members of the GEP of the AEDV were invited to participate in the survey. The final group comprised 46 members from various areas of Spain and with substantial experience in managing psoriasis. A 3-round Delphi process was used to reach consensus. Consistent agreement and consistent disagreement (consensus) required the achievement of at least two of the following three criteria: Criterion 1, which was based on the position occupied by the mean on a scale of 1-9 and an SD <2; Criterion 2, which was based on the median and interquartile range (IQR) on a scale of 1-9; Criterion 3, which considered the percentage of the voting experts on a scale of 1-9. The items studied were definition of severity, therapeutic objectives, indications for systemic treatment and biologic therapy, induction and maintenance periods, therapeutic failure, loss of response, relapse and rebound, continuous and intermittent therapy, screening of patients before treatment, adherence to therapy, follow-up of treatment outcome, combination of drugs, transitioning and associated comorbidities. Consistent agreement or disagreement (consensus) was achieved for 198 items (agreement, 3 criteria 146 items, 2 criteria 43 items; disagreement, 3 criteria 9 items, 2 criteria 0 items) based on the criteria described above. Completion of the Delphi consensus process enabled a broad and experienced group of Spanish psoriasis experts to provide useful and practical guidelines for the management and treatment of patients with moderate-to-severe psoriasis, particularly in areas where evidence is lacking.
Collapse
Affiliation(s)
- E Daudén
- Dermatology Department, IIS-IP, Hospital Universitario La Princesa, Madrid, Spain
| | - L Puig
- Dermatology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - C Ferrándiz
- Dermatology Department, Hospital Germans Trías i Pujol, Barcelona, Spain
| | - J L Sánchez-Carazo
- Dermatology Department, Hospital General Universitario de Valencia, Valencia, Spain
| | | | | |
Collapse
|
3
|
Leeb BF, Haindl PM, Brezinschek HP, Mai HTH, Deutsch C, Rintelen B. Patient-centered psoriatic arthritis (PsA) activity assessment by Stockerau Activity Score for Psoriatic Arthritis (SASPA). BMC Musculoskelet Disord 2015; 16:73. [PMID: 25887796 PMCID: PMC4393861 DOI: 10.1186/s12891-015-0512-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 02/27/2015] [Indexed: 11/30/2022] Open
Abstract
Background To investigate whether a modified Rheumatoid Arthritis Disease Activity Index-5 could be applied as a routine assessment tool for psoriatic arthritis (PsA) patients. Methods Ninety-seven PsA outpatients (mean age 49.78 years; age range 23–80 years; 49 male, 48 female), completed a prototype questionnaire. Tender and swollen joint counts, including enthesiopathy, physician’s assessment of disease activity on a visual analog scale (MDglob), erythrocyte sedimentation rate, and patient satisfaction with disease status (PatSat: 1 = excellent to 5 = unsatisfactory) were recorded. Factorial analysis was performed and alpha, as a measure of reliability, and tau were calculated. The ultimate five-item questionnaire, calculated by (Q1 + Q2 + Q3 + Q4 + Q5)/5, was then handed over to 152 PsA outpatients (mean age 54.02 years; age range 26–80 years; 82 male, 70 female), and analyzed accordingly. Results Analyzing the internal consistency of the prototype questionnaire revealed the highest alpha value of 0.849, on deleting the question targeting disease course. Alpha for the final Stockerau Activity Score for Psoriatic Arthritis (SASPA) was 0.875, with all items contributing to the final result (item loading from 0.573 to 0.910). Kendall’s tau for the relationship between SASPA scores and swollen joint count, tender joint count, and MDglob was 0.34, 0.416, and 0.392, respectively. The sensitivity of the questionnaire to change was demonstrated in patients starting treatment with a tumor necrosis factor blocker (standardized mean difference: 2.1). Conclusion The SASPA questionnaire constitutes a fully patient-administered tool to monitor PsA activity. Its reliability, convergent validity, and sensitivity to change were demonstrated.
Collapse
Affiliation(s)
- Burkhard F Leeb
- 2nd Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Landstrasse 18, A-2000, Stockerau, Austria. .,Private Rheumatology Office, Babogasse 20, A-2020, Hollabrunn, Austria. .,Department for Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 2, A-8036, Graz, Austria.
| | - Pia M Haindl
- 2nd Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Landstrasse 18, A-2000, Stockerau, Austria.
| | - Hans-Peter Brezinschek
- Department for Rheumatology and Immunology, Medical University of Graz, Auenbruggerplatz 2, A-8036, Graz, Austria.
| | - Harsono T H Mai
- 2nd Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Landstrasse 18, A-2000, Stockerau, Austria.
| | - Christoph Deutsch
- 2nd Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Landstrasse 18, A-2000, Stockerau, Austria.
| | - Bernhard Rintelen
- 2nd Department of Medicine, Center for Rheumatology, Lower Austria, State Hospital Stockerau, Karl Landsteiner Institute for Clinical Rheumatology, Landstrasse 18, A-2000, Stockerau, Austria.
| |
Collapse
|
4
|
Chou CT. Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis. Int J Rheum Dis 2012; 15:507-11. [PMID: 23253232 DOI: 10.1111/1756-185x.12006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The pathogenesis of most rheumatic diseases remains unknown. It is believed that both genetic and environmental factors play a pivotal role in the development of synovial inflammation in rheumatoid arthritis (RA), spondyloarthritis (SpA) and osteoarthritis (OA). In the last two decades, there have been many immunopathologic studies on RA, SpA and OA, and the findings revealed different types of arthritis may also present different pathologic patterns. These included higher vascularity and increased infiltration with CD163 macrophages and neutrophils, but relatively low values for lining cell (LL) hyperplasia in SpA synovium. However, the increased LL hyperplasia, as well as CD1a+ cells and the presence of intracellular citrullinated protein were more prominent in RA than in SpA synovitis. Anti-tumor necrosis factor alpha (anti-TNFα) therapy can significantly reduce synovial LL hyperplasia, vascularity and mononuclear cells infiltration in the majority of RA or SpA patients. This may explain why clinically, arthritis patients can get significant improvement after TNFα blocker treatment.
Collapse
Affiliation(s)
- Chung-Tei Chou
- Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
| |
Collapse
|
5
|
Saad AA, Hyrich KL, Ashcroft DM. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis. Expert Opin Drug Saf 2011; 10:219-26. [PMID: 21208138 DOI: 10.1517/14740338.2010.516250] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Anti-TNF therapies have been introduced for the management of psoriatic arthritis (PsA). There is a need to assess their effectiveness and safety in clinical practice. AREAS COVERED This review examines the emerging evidence of effectiveness, safety and drug persistence of anti-TNF therapies in PsA. It also assesses their impact on quality of life and physical functioning in patients with PsA, as well as potential predictors associated with changes in these domains. Several studies from different countries have demonstrated the effectiveness of the anti-TNF therapies in the management of PsA. These therapies have also been shown to be safe and well tolerated over a median usage of 3 years when compared to conventional disease modifying antirheumatic drugs. They also improved quality of life and physical functioning of patients suffering from PsA. EXPERT OPINION Anti-TNF therapies are effective and safe in the management of PsA. Improvements in disease activity have been shown to be associated with improvements in quality of life of PsA patients receiving anti-TNF therapies.
Collapse
Affiliation(s)
- Amr A Saad
- Egyptian Pharmacovigilance Centre, Central Administration for Pharmaceutical Affairs, Ministry of Health, Cairo, PO Box 11451, Egypt
| | | | | |
Collapse
|